Integrative Biomarker Prediction Framework
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current computational methods for predicting biomarkers are inefficient and cost-ineffective due to reliance on single types of data, failing to provide significant improvements in disease or medical condition analysis, and are prone to bias from disparate input data.
Innovation Solution
An integrated computational framework that combines various omics data types, including genomics, transcriptomics, and proteomics, using algorithms for clustering, feature selection, and optimization, with a focus on non-coding RNA and automated parameter optimization to minimize bias and improve accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single type of data (genomics, transcriptomics, or proteomics) is used for computational prediction, then the analysis process is simpler, but the prediction accuracy and ability to detect disease-related biomarkers is insufficient
Solution Approach 1:
The patent combines multiple types of omics data (genomics, transcriptomics, and proteomics) into an integrated computational framework. This merging of data sources allows the system to leverage complementary information from each data type, thereby improving biomarker prediction accuracy while managing the complexity through unified analysis pipelines.
Solution Approach 2:
The computational framework is designed to handle multiple types of biological data simultaneously, making it a universal system that can process genomics, transcriptomics, and proteomics data. This multi-functionality enables the system to adapt to different data types and experimental designs while maintaining consistent analysis standards.
2Reliability
If multiple types of omics data are integrated, then the biomarker prediction accuracy improves, but the computational complexity and resource requirements increase
Solution Approach 1:
The computational framework segments the analysis process into distinct modules that handle different types of omics data separately before integration. This segmentation allows each data type to be processed with appropriate algorithms while maintaining overall system coherence, thereby improving reliability without overwhelming computational complexity.
Solution Approach 2:
The patent introduces intermediary computational layers that mediate between raw multi-omics data and final biomarker predictions. These intermediary processing steps include data normalization, feature selection, and integration algorithms that bridge different data types, enhancing prediction reliability while managing computational complexity through structured intermediate representations.
3Quantity of substance
If comprehensive omics data analysis is performed, then more biomarkers can be discovered, but the time and cost efficiency decreases
Solution Approach 1:
The computational framework performs preliminary data processing, filtering, and feature selection before comprehensive biomarker analysis. This preliminary action reduces the dimensionality of the data and identifies promising candidates early, enabling more biomarkers to be discovered while maintaining time and cost efficiency by avoiding exhaustive analysis of all data points.
Solution Approach 2:
The patent applies partial analysis strategies where not all data points are processed with the same level of detail. Instead, the system focuses computational resources on the most promising regions or features identified through preliminary screening, thereby discovering more biomarkers efficiently by concentrating analysis where it yields the highest return.
Data Source
AI summary
An approach is provided to computationally identify biomarkers associated with diseases and medical conditions. The procedure first identifies biomarkers individually at the DNA, RNA and proteome levels. Then provides a methodology to integrate the single-source biomarkers and perform dimensionality reduction in order to detect the most informative subset of biomarkers that better distinguish samples between two biological conditions (disease vs normal samples). The dimensionality reduction step minimizing biases due to unnecessary or partially correlated biomarkers and significantly reduces the search space of possible biomarkers. An algorithm is also described for the automated optimization of the proposed DNA-seq and RNA-seq pipelines.